stanolone
Small moleculeexperimental
STANOLONE, also known as dihydrotestosterone, is a potent androgenic metabolite of testosterone and anabolic agent for systemic use. It may be used as a replacement of male sex steroids in men who have androgen deficiency, for example as a result of the loss of both testes, and also the treatment of certain rare forms of aplastic anemia which are or may be responsive to anabolic androgens. — NCATS
Clinical trial activity
5 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2003 (NCT00588185)
Timeline
Indications
Approved for
Mechanism of action
- Androgen ReceptorAGONIST
AR agonist
Chemistry & pharmacology
Loading structure…
SMILES
C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@]34C)[C@@H]1CC[C@@H]2O- Mol. weight
- 290.4403 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaAndrostanolone ↗
- NCATS08J2K08A3Y ↗
- ChEMBLCHEMBL27769 ↗
Also known as
- 17beta-hydroxy-5alpha-androstan-3-one
- 17beta-hydroxy-5alpha-androstan-3-one
- 17beta-hydroxy-5alpha-androstane-3-one
- 17beta-hydroxy-5alpha-androstane-3-one
- 17beta-hydroxyandrostan-3-one
- 17beta-hydroxyandrostan-3-one
- 17β-hydroxy-3-oxo-5α-androstanone
- 17β-hydroxy-3-oxo-5α-androstanone
- 17β-hydroxy-5α-androstan-3-one
- 17β-hydroxy-5α-androstan-3-one
- 18f dihydrotestosterone
- 18f dihydro-testosterone
- 4-dihydrotestosterone
- 4-dihydrotestosterone
- 5alpha-dihydrotestosterone
- 5alpha-dihydrotestosterone
- 5alpha-dihydrotestosterone
- 5α-dht
- 5α-dht
- androlone
- androstanolone
- androstanolone
- androstanolone
- androstanolone
- androstanolone
- dht
- dht
- dihydrotestosteron
- dihydrotestosteron
- dihydrotestosterone
- dihydrotestosterone
- dihydrotestosterone
- dihydrotestosterone
- dihydrotestostérone
- dihydrotestostérone
- neodrol
- neodrol
- neodrol
- neodrol
- neodrol
- neodrol
- stanolone
- stanolone
- stanolone
- stanolone
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02297386 | Phase 1 | Nov 1, 2014 | Cornell University |
| NCT01724619 | Early Phase 1 (Phase 1) | Nov 1, 2012 | Wake Forest University |
| NCT00490022 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2007 | Besins Healthcare, National Institute on Aging (NIA), University of Washington |
| NCT00163566 | Phase 2 | Oct 1, 2004 | Besins Healthcare |
| NCT00588185 | N/A | Feb 1, 2003 | Cornell University |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Besins Healthcare | For profit | 2 | 1 | 1 | 2004 |
| Cornell University | Academic/Hospital | 2 | 2 | 2 | 2003 |
| National Institute on Aging (NIA) | Government | 1 | 0 | 1 | 2007 |
| University of Washington | Academic/Hospital | 1 | 1 | 1 | 2007 |
| Wake Forest University | Academic/Hospital | 1 | 1 | 1 | 2012 |
5 organizations
Page 1 / 1